The natural immune molecules urinary Tamm-Horsfall protein and pentraxin 3 as predictors for recurrent urinary tract infection severity: a single-center self-control study.

IF 3 3区 医学 Q1 UROLOGY & NEPHROLOGY
Renal Failure Pub Date : 2025-12-01 Epub Date: 2025-01-08 DOI:10.1080/0886022X.2024.2449574
Zongping Li, Yingru Xu, Qian Wang, Gang Yuan, Jing Shu, Shiwei Liu, Xuezhong Gong
{"title":"The natural immune molecules urinary Tamm-Horsfall protein and pentraxin 3 as predictors for recurrent urinary tract infection severity: a single-center self-control study.","authors":"Zongping Li, Yingru Xu, Qian Wang, Gang Yuan, Jing Shu, Shiwei Liu, Xuezhong Gong","doi":"10.1080/0886022X.2024.2449574","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The innate immune defense plays a pivotal role in protecting the urinary tract from uropathogenic invasion and maintaining immune homeostasis. Dysregulation of the innate immune system can result in recurrent urinary tract infections (RUTI) due to heightened susceptibility to uropathogens. Despite this, predicting the risk of recurrence and the degree of immune compromise in patients who have had one urinary tract infection remains challenging. Also identifying which patients are more susceptible to developing pyelonephritis rather than the more local disease of cystitis is imperfect, although delayed diagnosis of a UTI is a good indicator for developing pyelonephritis. This study aims to assess the potential of urinary Tamm-Horsfall protein (THP) and Pentraxin 3 (PTX3) as predictors of RUTI symptom severity and recurrence, while also evaluating the efficacy of the Chinese herbal formulation Tailin Formula (TLF) as a clinical therapeutic intervention for RUTI.</p><p><strong>Methods: </strong>A single-center cohort study was conducted involving 142 participants, consisting of 31 healthy individuals (non-RUTI group, <i>n</i> = 31) and 111 patients with RUTI. The RUTI patients were divided into two groups: one group received continuous low-dose antibiotic therapy (CLAT group, <i>n</i> = 55), and the other group received herbal preparations (Tailin formula) (TLF group, <i>n</i> = 56). All patients received consistent lifestyle guidance. Descriptive analysis was performed on the RUTI cohort.</p><p><strong>Results: </strong>Urinary THP levels were significantly lower in RUTI patients (TLF and CLAT groups) compared to the non-RUTI, whereas PTX3 levels showed a tendency toward elevation. After treatment, urinary THP levels were markedly higher in the TLF group (27.43 ± 7.07) compared to pretreatment levels (10.00 ± 2.79), while levels remained lower in the CLAT group (8.91 ± 2.23) than in the TLF group. Urinary PTX3 levels decreased post-treatment in both groups after treatment than before (CLAT: 0.30 ± 0.13 vs. 1.04 ± 0.38; TLF: 0.29 ± 0.12 vs. 1.15 ± 0.36). Additionally, THP was negatively correlated with renal tubular injury markers NAG/Cr and β2-MG in RUTI patients (<i>r</i> = -0.5041 and -0.6169, respectively), while PTX3 showed a positive correlation with NAG/Cr and β2-MG (<i>r</i> = 0.28 and 0.498, respectively). Notably, as RUTI symptoms improved and recurrence rates decreased, urinary THP levels increased, while PTX3 levels decreased.</p><p><strong>Conclusion: </strong>This study suggests that urinary THP and PTX3 are likely involved in the pathogenesis of RUTI. These biomarkers may serve as valuable predictors for assessing symptom severity, recurrence risk, and therapeutic efficacy in patients with RUTI at risk of disease progression.</p>","PeriodicalId":20839,"journal":{"name":"Renal Failure","volume":"47 1","pages":"2449574"},"PeriodicalIF":3.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721855/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Renal Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/0886022X.2024.2449574","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The innate immune defense plays a pivotal role in protecting the urinary tract from uropathogenic invasion and maintaining immune homeostasis. Dysregulation of the innate immune system can result in recurrent urinary tract infections (RUTI) due to heightened susceptibility to uropathogens. Despite this, predicting the risk of recurrence and the degree of immune compromise in patients who have had one urinary tract infection remains challenging. Also identifying which patients are more susceptible to developing pyelonephritis rather than the more local disease of cystitis is imperfect, although delayed diagnosis of a UTI is a good indicator for developing pyelonephritis. This study aims to assess the potential of urinary Tamm-Horsfall protein (THP) and Pentraxin 3 (PTX3) as predictors of RUTI symptom severity and recurrence, while also evaluating the efficacy of the Chinese herbal formulation Tailin Formula (TLF) as a clinical therapeutic intervention for RUTI.

Methods: A single-center cohort study was conducted involving 142 participants, consisting of 31 healthy individuals (non-RUTI group, n = 31) and 111 patients with RUTI. The RUTI patients were divided into two groups: one group received continuous low-dose antibiotic therapy (CLAT group, n = 55), and the other group received herbal preparations (Tailin formula) (TLF group, n = 56). All patients received consistent lifestyle guidance. Descriptive analysis was performed on the RUTI cohort.

Results: Urinary THP levels were significantly lower in RUTI patients (TLF and CLAT groups) compared to the non-RUTI, whereas PTX3 levels showed a tendency toward elevation. After treatment, urinary THP levels were markedly higher in the TLF group (27.43 ± 7.07) compared to pretreatment levels (10.00 ± 2.79), while levels remained lower in the CLAT group (8.91 ± 2.23) than in the TLF group. Urinary PTX3 levels decreased post-treatment in both groups after treatment than before (CLAT: 0.30 ± 0.13 vs. 1.04 ± 0.38; TLF: 0.29 ± 0.12 vs. 1.15 ± 0.36). Additionally, THP was negatively correlated with renal tubular injury markers NAG/Cr and β2-MG in RUTI patients (r = -0.5041 and -0.6169, respectively), while PTX3 showed a positive correlation with NAG/Cr and β2-MG (r = 0.28 and 0.498, respectively). Notably, as RUTI symptoms improved and recurrence rates decreased, urinary THP levels increased, while PTX3 levels decreased.

Conclusion: This study suggests that urinary THP and PTX3 are likely involved in the pathogenesis of RUTI. These biomarkers may serve as valuable predictors for assessing symptom severity, recurrence risk, and therapeutic efficacy in patients with RUTI at risk of disease progression.

天然免疫分子尿Tamm-Horsfall蛋白和戊烷素3作为复发性尿路感染严重程度的预测因子:单中心自我控制研究
目的:先天免疫防御在保护尿路免受尿路病原体侵袭和维持免疫稳态中起着关键作用。先天免疫系统的失调可导致复发性尿路感染(RUTI),由于对尿路病原体的易感性增加。尽管如此,预测一次尿路感染患者的复发风险和免疫损害程度仍然具有挑战性。此外,尽管尿路感染的延迟诊断是肾盂肾炎的一个很好的指标,但确定哪些患者更容易发生肾盂肾炎,而不是更局部的膀胱炎,尚不完善。本研究旨在评估尿中tam - horsfall蛋白(THP)和penttraxin 3 (PTX3)作为RUTI症状严重程度和复发预测因子的潜力,同时评估中药复方泰林方(TLF)作为RUTI临床治疗干预的疗效。方法:采用单中心队列研究,纳入142名受试者,包括31名健康个体(非RUTI组,n = 31)和111名RUTI患者。将RUTI患者分为两组,一组给予持续低剂量抗生素治疗(CLAT组,n = 55),另一组给予中药制剂(泰林方)治疗(TLF组,n = 56)。所有患者均接受一致的生活方式指导。对RUTI队列进行描述性分析。结果:与非RUTI患者相比,RUTI患者(TLF和CLAT组)尿THP水平显著降低,而PTX3水平呈升高趋势。治疗后,TLF组尿THP水平(27.43±7.07)明显高于治疗前(10.00±2.79),CLAT组尿THP水平(8.91±2.23)明显低于治疗前(10.00±2.79)。两组患者治疗后尿PTX3水平均低于治疗前(CLAT: 0.30±0.13 vs 1.04±0.38;TLF: 0.29±0.12 vs. 1.15±0.36)。此外,在RUTI患者中,THP与肾小管损伤标志物NAG/Cr和β2-MG呈负相关(r分别为-0.5041和-0.6169),PTX3与NAG/Cr和β2-MG呈正相关(r分别为0.28和0.498)。值得注意的是,随着RUTI症状的改善和复发率的降低,尿THP水平升高,而PTX3水平下降。结论:本研究提示尿THP和PTX3可能参与RUTI的发病机制。这些生物标志物可以作为评估RUTI患者疾病进展风险的症状严重程度、复发风险和治疗效果的有价值的预测指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Renal Failure
Renal Failure 医学-泌尿学与肾脏学
CiteScore
3.90
自引率
13.30%
发文量
374
审稿时长
1 months
期刊介绍: Renal Failure primarily concentrates on acute renal injury and its consequence, but also addresses advances in the fields of chronic renal failure, hypertension, and renal transplantation. Bringing together both clinical and experimental aspects of renal failure, this publication presents timely, practical information on pathology and pathophysiology of acute renal failure; nephrotoxicity of drugs and other substances; prevention, treatment, and therapy of renal failure; renal failure in association with transplantation, hypertension, and diabetes mellitus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信